This is a prospective, observational cohort study aimed to explore the influence of anxiety and depression to long term survival in nasopharyngeal carcinoma patients.
Nasopharyngeal carcinoma (NPC) is endemic in Southern China and Southeast Asia. Radiotherapy (RT) and chemotherapy are the mainstays of therapy for NPC because these tumors are biologically highly radiosensitive and chemosensitive. Anxiety and depression symptoms were common psychological symptoms around the time of cancer diagnosis and were often persistent during cancer treatment. Psychological symptoms are associated with prolonged hospital stays, lower quality of life, and worse treatment adherence among patients with cancer. Depressive symptoms have been demonstrated to predict early mortality among patients with some kinds of cancer. But among NPC patients, the influence of anxiety and depression symptoms to long term survival have not be explored. Therefore, this prospective, observational cohort study aimed to explore the influence of anxiety and depression to long term survival in NPC patients.
Study Type
OBSERVATIONAL
Enrollment
1,000
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
RECRUITINGProgress-free survival
Progress-free survival is calculated from the date of registration to the date of the first progress at any site.
Time frame: 3 years
Anxiety related measure
Hospital Anxiety and Depression Scale (HADS) and Hamilton Anxiety Rating Scale (HAMA) will be used during the assessment.
Time frame: Baseline, completion of radiation therapy (up to 12 weeks)
Distress related measure
Hospital Anxiety and Depression Scale (HADS) and Hamilton Depression Rating Scale (HAMD) will be used during the assessment.
Time frame: Baseline, completion of radiation therapy (up to 12 weeks)
Overall Survival(OS)
The OS was defined as the duration from the date of registration assignment to the date of death from any cause or censored at the date of the last follow-up.
Time frame: 3 years
Locoregional Relapse-Free Survival(LRFS)
The LRFS is evaluated and calculated from the date of registration until the day of first locoregional relapse or until the date of the last follow-up visit.
Time frame: 3 years
Distant Metastasis-Free Survival (DMFS)
The DMFS is evaluated and calculated from the date of registration until the day of first distant metastases or until the date of the last follow-up visit.
Time frame: 3 years
Complete Response (CR)
CR assessed by independent reviewers, according to the Modified Response Evaluation Criteria in Solid Tumors (RECIST) from the National Cancer Institute (NCI). Disease response evaluated after the completion of the treatment. Complete response defined as the complete disappearance of the target and non-target lesion(s) identified at baseline after radiological evaluation by Magnetic Resonance Imaging (MRI) only.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: completion of radiation therapy (up to 12 weeks)
Weight Loss
Weight loss was calculated as the relative percent of weight changes between weight measurement before and after the nasopharyngeal carcinoma treatment. Weight loss was calculated from the following formula:（ pro-treatment body weight - post-treatment body weight）/ pro-treatment body weight.
Time frame: Baseline, completion of radiation therapy (up to 12 weeks)